Commercial Readiness ProKidney’s RMAT designation and late-stage program, coupled with the appointment of a Chief Commercial Officer, signal a movement toward commercialization. This creates sales opportunities in market access planning, payer strategy, pricing models, and multi-channel field deployment. Target CMOs, contract sales organizations, patient support services, and health economics vendors to prepare for launch.

Manufacturing Partnerships Autologous cellular therapies require validated GMP manufacturing and a robust supply chain. There are strong opportunities to partner with CDMOs and CMOs for process development, scale-up, fill-finish, quality control, and cold-chain logistics to support a future commercial supply network.

IT and Systems Enablement ProKidney already utilizes AWS, SAP, and Sage ERP, suggesting appetite for deeper data integration and digital operations. Potential sales targets include LIMS and EDC providers, data analytics platforms, ERP optimization, and cloud security services to improve trial management and manufacturing governance.

Strategic Partnerships With meaningful revenue and ongoing expansion, ProKidney is well positioned for licensing, co-development, or strategic alliances in CKD and diabetes. Ideal partners include large pharma companies pursuing diabetic nephropathy programs and investors or IR platforms to support growth and capital markets communication.

Regulatory Strategy RMAT designation and ongoing Phase 2/3 activity indicate ongoing regulatory engagement. Opportunities exist to provide regulatory affairs consulting, trial design optimization, and real-world evidence planning, as well as support for FDA interactions and future RMAT-adjacent submissions.